Dupixent nears new indication in USA

French pharma major Sanofi (Euronext: SAN) and US biotech Regeneron’s (Nasdaq: REGN) blockbuster monoclonal antibody Dupixent (dupilumab) is nearing another indication in the USA.

The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent to treat children aged one to 11 years with eosinophilic esophagitis (EoE).

If approved, Dupixent would be the first and only treatment indicated in the USA for children aged one to 11 with EoE, a disease driven by type two inflammation that impacts the ability to eat.